Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
Loyola University Medical Center · Palmetto Hematology Oncology · +8 more institutions
Abstract
PURPOSE: This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients. PATIENTS AND METHODS: This is a phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study. Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic stem-cell transplantation in first or second complete or partial remission were eligible. Patients received granulocyte colony-stimulating factor (G-CSF; 10 microg/kg) subcutaneously daily for up to 8 days. Beginning on evening of day 4 and continuing daily for up to 4 days, patients received either…
Citation impact
- FWCI
- 38.91
- Percentile
- 100%
- References
- 34
Authors
10- JFJohn F. DiPersioCorresponding
Loyola University Medical Center
- INIvana N. Micallef
Loyola University Medical Center, Palmetto Hematology Oncology
- PJPatrick J. Stiff
City Of Hope National Medical Center, Loyola University Medical Center, Cleveland Clinic, Oregon Health & Science University, Virginia Commonwealth University, Loyola University Chicago, Washington University in St. Louis, GVD Corporation (United States), Mayo Clinic in Arizona
- BJBrian J. Bolwell
City Of Hope National Medical Center, Loyola University Medical Center, Cleveland Clinic, Oregon Health & Science University, Virginia Commonwealth University, Loyola University Chicago, Washington University in St. Louis, GVD Corporation (United States), Mayo Clinic in Arizona
- RTRichard T. Maziarz
City Of Hope National Medical Center, Loyola University Medical Center, Cleveland Clinic, Oregon Health & Science University, Virginia Commonwealth University, Loyola University Chicago, Washington University in St. Louis, GVD Corporation (United States), Mayo Clinic in Arizona
Topics & keywords
- Plerixafor
- Medicine
- Granulocyte colony-stimulating factor
- Placebo
- Surgery
- CXCR4 antagonist
- Transplantation
- Clinical endpoint
- Good health and well-being